Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
I-MAB ( (IMAB) ) has provided an announcement.
On October 23, 2025, I-MAB released updated results from its Phase I monotherapy study of Givastomig, a bispecific antibody targeting Claudin 18.2, in patients with advanced gastroesophageal carcinoma. The study, which involves patients from the US and China, demonstrated that Givastomig was well-tolerated and showed promising efficacy, with no dose-limiting toxicities observed up to the highest tested doses. These findings could enhance I-MAB’s position in the oncology market by potentially offering a new treatment option for patients with limited alternatives.
The most recent analyst rating on (IMAB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-MAB is a biopharmaceutical company focused on the development of innovative biologics for the treatment of cancer and autoimmune diseases. The company is known for its work on novel monoclonal antibodies and bispecific antibodies, with a particular emphasis on targeting specific cancer markers to improve treatment efficacy.
Average Trading Volume: 2,659,080
Technical Sentiment Signal: Buy
Current Market Cap: $406.3M
See more insights into IMAB stock on TipRanks’ Stock Analysis page.